Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 3:12:669296.
doi: 10.3389/fneur.2021.669296. eCollection 2021.

Ketogenic Diet in the Treatment of Super-Refractory Status Epilepticus at a Pediatric Intensive Care Unit: A Single-Center Experience

Affiliations

Ketogenic Diet in the Treatment of Super-Refractory Status Epilepticus at a Pediatric Intensive Care Unit: A Single-Center Experience

Markus Breu et al. Front Neurol. .

Abstract

Background: To evaluate the use of the ketogenic diet (KD) for treatment of super-refractory status epilepticus (SRSE) at a pediatric intensive care unit (PICU). Design: A retrospective analysis of all pediatric patients treated for SRSE with the KD at our center was performed using patient data from our prospective longitudinal KD database. Setting: SRSE is defined as refractory SE that continues or recurs 24 h or more after initiation of anesthetic drugs. We describe the clinical and electroencephalographic (EEG) findings of all children treated with KD at our PICU. The KD was administered as add-on after failure of standard treatment. Response was defined as EEG seizure resolution (absence of seizures and suppression-burst ratio ≥50%). Patients: Eight consecutive SRSE patients (four females) treated with KD were included. Median age at onset of SRSE was 13.6 months (IQR 0.9-105), and median age at KD initiation was 13.7 months (IQR 1.9 months to 8.9 years). Etiology was known in 6/8 (75%): genetic in 4 (50%), structural in 1 (12.5%), and autoimmune/inflammatory in 1 (12.5%). Main Results: Time from onset of SRSE to initiation of KD was median 6 days (IQR 1.3-9). Time until clinically relevant ketosis (beta-hydroxybutyrate (BHB) >2 mmol/L in serum) was median 68.0 h (IQR 27.3-220.5). Higher ketosis was achieved when a higher proportion of enteral feeds was possible. Four (50%) patients responded to KD treatment within 7 days. During follow-up (median 4.2 months, IQR 1.6-12.3), 5/8 patients-three of them responders-died within 3-12 months after SRSE. Conclusions: In eight patients with SRSE due to severe etiologies including Alpers syndrome, we report an initial 50% response to KD. KD was used early in SRSE and sufficient levels of ketosis were reached early in most patients. Higher ketosis was achieved with combined enteral and parenteral feedings.

Keywords: beta-hydroxybutyrate; ketogenic diet; parenteral diet; pediatric; status epilepticus.

PubMed Disclaimer

Conflict of interest statement

AD has received travel reimbursement and speaker honoraria from SHS, Nutricia and Vitaflo. PT-S has received travel reimbursement from SHS, Nutricia and Vitaflo. MF received travel reimbursement from SHS, Nutricia. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Ketosis after KD initiation. Ketone levels of beta-hydroxybutyrate (BHB) in serum as trajectories from day 1 to day 8. Relevant ketosis (>2 mmol/l) is marked above the red line. Detailed data on ketosis within the first days of KD were available in seven patients: while five patients reached relevant ketosis, the other two (patient 8 and patient 4) showed maximum levels of 0.7 and 0.2 mmol/l, respectively. In patient 8 (FIRES) corticosteroids were administered 3 days before KD start and overlapped for the first 3 days hence delaying ketosis.

Similar articles

Cited by

References

    1. Neville BG, Chin RF, Scott RC. Childhood convulsive status epilepticus: epidemiology, management and outcome. Acta Neurol Scand. (2007) 115:21–4. 10.1111/j.1600-0404.2007.00805.x - DOI - PubMed
    1. Lewena S, Young S. When benzodiazepines fail: how effective is second line therapy for status epilepticus in children? Emerg Med Australas. (2006) 18:45–50. 10.1111/j.1742-6723.2006.00807.x - DOI - PubMed
    1. Eriksson K, Metsäranta P, Huhtala H, Auvinen A, Kuusela AL, Koivikko M. Treatment delay and the risk of prolonged status epilepticus. Neurology. (2005) 65:1316–8. 10.1212/01.wnl.0000180959.31355.92 - DOI - PubMed
    1. Barzegar M, Mahdavi M, Galegolab Behbehani A, Tabrizi A. Refractory convulsive status epilepticus in children: etiology, associated risk factors and outcome. Iran J Child Neurol. (2015) 9:24–31. - PMC - PubMed
    1. Jayalakshmi S, Ruikar D, Vooturi S, Alladi S, Sahu S, Kaul S, et al. . Determinants and predictors of outcome in super refractory status epilepticus–a developing country perspective. Epilepsy Res. (2014) 108:1609–1617. 10.1016/j.eplepsyres.2014.08.010 - DOI - PubMed

LinkOut - more resources